Following its $8.9 million Series B capital raise in March, Okyanos Heart Institute is rapidly approaching the day when it will be able to treat the first heart patient using autologous adipose derived regenerative cells (ADRCs) in the Bahamas. Adipose, or fat, is the richest source of regenerative cells in the body and the term "autologous" simply means that the cells are derived from the same patient undergoing the cell therapy treatment.